When you build a company around sleep, you better be wide awake. ProSomnus just secured up to $38M in a strategic investment from Catalio Capital Management to scale what they call Smart Sleep...
When you build a company around sleep, you better be wide awake. ProSomnus just secured up to $38M in a strategic investment from Catalio Capital Management to scale what they call Smart Sleep Medicine. Translation for the boardroom and the bedroom alike: this is about turning oral appliance therapy into a data-driven, sensor-enabled, remotely monitored standard of care. Not a side hustle to CPAP. A contender.
Congratulations to Co-Founder and CEO Len Liptak and Executive Chair Laing F. Rikkers. And respect to Co-Founders Dave Kuhns and Sung Kim for laying the technical and clinical groundwork years ago when dental sleep medicine was still fighting for a seat at the grown-ups’ table. Building 187,500 delivered devices and a network of more than 4,000 medical providers does not happen because you wish hard. It happens because you engineer hard.
Catalio Capital Management does not place bets for sport. They hunt durable science and scalable platforms. This capital is earmarked to advance next-gen sensor-enabled oral devices, remote patient monitoring, and proprietary diagnostics. In other words, ProSomnus is not just fitting mouths. They are fitting medicine with feedback loops. Sleep becomes measurable. Adherence becomes visible. Outcomes stop being a shrug.
And let’s not pretend the road was smooth jazz. After a public listing and a Chapter 11 restructuring in 2024, ProSomnus recapitalized, went private, secured $30M in financing, and kept shipping. That is not luck. That is operational stamina. CFO Brian Dow has been steering the financial architecture since 2023, and you do not navigate restructurings and strategic raises without discipline in the numbers and conviction in the narrative.
The real story is market gravity. Obstructive Sleep Apnea affects more than 1 billion people globally. CPAP works, but adherence has always been the elephant in the bedroom. ProSomnus builds FDA-cleared, precision, mass-customized intraoral devices that are smaller, stronger, and engineered for comfort. If patients actually wear the therapy, the therapy actually works. It is amazing how that math checks out.
Now layer in sensors and remote monitoring. Suddenly the appliance is not a static piece of hardware. It is a node in a clinical intelligence network. Dentists and physicians get nightly insights. Payers get data. Patients get treatment that fits their life instead of hijacking it.
This raise is not just about capital. It is about conviction that sleep medicine can be smarter, more connected, and more accountable. ProSomnus is betting that precision in the mouth can drive precision in outcomes. Catalio is betting that this precision scales.